報價延遲最少15分鐘:2024/05/18 10:32 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.88/-1.22
|
|
企業價值
77.27M
|
| 資產負債 |
|
每股賬面淨值
2.15
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/18 10:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. |